ProCE Banner Activity

Advances in IBD Precision Medicine With Therapeutic Drug Monitoring

Slideset Download

Gain expert insights on current best practices for therapeutic drug monitoring in patients with IBD.

Released: January 19, 2022

Expiration: January 18, 2023

Share

Faculty

Marla Dubinsky

Marla Dubinsky, MD

Professor of Pediatrics and Medicine
Chief, Division of Pediatric Gastroenterology and Nutrition
Co-Director, Susan and Leonard Feinstein IBD Clinical Center
Mount Sinai Kravis Children’s Hospital
Ichan School of Medicine, Mount Sinai New York
New York, New York

Bruce E. Sands

Bruce E. Sands, MD, MS

Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Chief, Division of Gastroenterology
Mount Sinai Health System
New York, New York

Provided by

Provided by the American Gastroenterology Association.

ProCE Banner

Supporters

Supported by educational grants from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Takeda Pharmaceuticals U.S.A., Inc.

Faculty Disclosure

Primary Author

Marla Dubinsky, MD

Professor of Pediatrics and Medicine
Chief, Division of Pediatric Gastroenterology and Nutrition
Co-Director, Susan and Leonard Feinstein IBD Clinical Center
Mount Sinai Kravis Children’s Hospital
Ichan School of Medicine, Mount Sinai New York
New York, New York

Marla Dubinsky, MD: consultant/advisor/speaker: AbbVie, Abivax, AstraZeneca, Bristol Myers Squibb, Janssen, Lilly, Merck, Pfizer, Prometheus Biosciences, Takeda.

Bruce E. Sands, MD, MS

Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Chief, Division of Gastroenterology
Mount Sinai Health System
New York, New York

Bruce E. Sands, MD, MS: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen/Johnson & Johnson, Lilly, Merck, Pfizer, Takeda, Teva.